Reduced-drug treatment becoming common in Paris
Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure
Doravirine/islatravir just as effective as Biktarvy in previously untreated people
NRTI-sparing regimen effective for children and adolescents
Dolutegravir alone maintains HIV suppression in those treated early
Real-world data confirm the efficacy of dolutegravir-based dual therapy
Dolutegravir plus darunavir superior to three-drug darunavir combination in second-line treatment
Are people with a shorter history of viral suppression at greater risk of failure of dolutegravir/lamivudine?
History of drug resistance or virological failure warrants caution when switching to dolutegravir plus lamivudine